Related Experiment Video

Updated: Jun 21, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis

Manav Korpal1, Jun Yan, Xin Lu

  • 1Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA.

Nature Medicine
|July 15, 2009
PubMed

Insights

Targeting the transforming growth factor-beta (TGF-beta) pathway early in breast cancer bone metastasis significantly reduces tumor spread. Disrupting TGF-beta signaling is less effective once bone lesions are established.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • The transforming growth factor-beta (TGF-beta) pathway is linked to breast cancer metastasis.
  • The in vivo dynamics and organ-specific roles of TGF-beta in metastasis remain unclear.

Purpose of the Study:

  • To investigate the in vivo dynamics and temporal-spatial involvement of the TGF-beta pathway in breast cancer bone metastasis.
  • To develop and utilize a novel xenograft model for real-time monitoring and manipulation of TGF-beta signaling in vivo.

Main Methods:

  • Engineered a xenograft model with conditional control of the TGF-beta-SMAD signaling pathway.
  • Incorporated a dual-luciferase reporter system to track metastatic burden and TGF-beta activity.
  • Investigated the effects of genetic/pharmacological disruption of TGF-beta signaling and bisphosphonates on osteolytic bone lesions.

Main Results:

  • Strong TGF-beta signaling in bone lesions was suppressed by targeting the TGF-beta-SMAD pathway and inhibiting osteoclast function.
  • Early disruption of TGF-beta signaling substantially reduced metastasis burden.
  • Intervention became less effective when bone lesions were well-established.

Conclusions:

  • The timing of TGF-beta pathway disruption is critical for reducing breast cancer metastasis burden in bone.
  • The developed in vivo system enables real-time analysis of metastasis-associated signaling pathways.
  • This strategy can accelerate the development and characterization of novel therapeutic agents for metastasis.

More Related Videos

Models of Bone Metastasis08:49

Models of Bone Metastasis

Published on: September 4, 2012

Spheroid Assay to Measure TGF-β-induced Invasion09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...